AI-generated analysis. Always verify with the original filing.
On March 5, 2026, Galmed Pharmaceuticals Ltd. held a Special General Meeting of Shareholders where the proposal described in the proxy statement furnished on February 9, 2026, was approved by shareholders with the requisite majority under the Israeli Companies Law.